AnaptysBio, Inc.

AnaptysBio, Inc. is a clinical-stage biotechnology company focused on developing immunology therapeutics for autoimmune and inflammatory diseases. Its lead product candidate is Rosnilimab, a selective pathogenic T cell deplete that completed a Phase 2b trial for moderate-to-severe rheumatoid arthritis. The company also has ANB033, a CD122 antagonist in Phase 1b for celiac disease and eosinophilic esophagitis; ANB101, a BDCA2 modulator antibody in Phase 1a targeting plasmacytoid dendritic cells; dostarlimab, a PD-1 antagonist for solid tumors; and Imsidolimab, an antibody inhibiting the interleukin-36 receptor in Phase 3 for generalized pustular psoriasis. Additionally, AnaptysBio advances preclinical and clinical antibody programs through collaborations with GSK and Vanda.

AnaptysBio, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol ANAB. Its shares trade in U.S. dollars (USD), as the company is headquartered in the United States. The NasdaqGS is a major U.S. stock exchange known for listing many technology and biotechnology companies. Investors can buy and sell ANAB shares during regular trading hours on this exchange, and the stock price is quoted in USD.

AnaptysBio operates in the Healthcare sector, specifically within the Biotechnology industry. As a clinical-stage biotechnology company, it focuses on researching and developing novel antibody-based therapies for autoimmune and inflammatory diseases. Biotechnology companies like AnaptysBio typically engage in high-risk, high-reward drug development, with products often requiring years of clinical trials and regulatory approvals before reaching the market. The company's pipeline includes candidates targeting rheumatoid arthritis, psoriasis, celiac disease, and other conditions, reflecting its specialization in immunology.

AnaptysBio, Inc. is headquartered in San Diego, California, United States. The company was incorporated in 2005 and originally operated as Anaptys Biosciences, Inc. before rebranding to AnaptysBio, Inc. in July 2006. San Diego is a major hub for biotechnology and life sciences research, providing access to talent and collaborative opportunities. The company focuses on developing immunology therapeutics for autoimmune and inflammatory diseases, with its research and development activities centered at its California headquarters.

AnaptysBio is a clinical-stage company, meaning it does not yet have approved products generating commercial revenue. Instead, it generates revenue primarily through collaboration agreements with larger pharmaceutical companies. The company has partnerships with GSK and Vanda, under which it advances antibody programs to preclinical and clinical milestones in exchange for research funding, milestone payments, and potential royalties. Its pipeline includes candidates like Rosnilimab (rheumatoid arthritis), Imsidolimab (generalized pustular psoriasis), and ANB033 (celiac disease and eosinophilic esophagitis). Success in clinical trials and regulatory approvals would enable future product sales, but currently the business model relies on collaboration income and equity financing to support operations.